Conformis, Inc. (CFMS)
CFMS Price and Sentiment
CFMS Latest news
Conformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant Reported
2021-11-08 09:00BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing.
Conformis, Inc. (CFMS) CEO Mark Augusti on Q3 2021 Results - Earnings Call Transcript
2021-11-03 20:10Conformis, Inc. (CFMS) CEO Mark Augusti on Q3 2021 Results - Earnings Call Transcript
ConforMIS (CFMS) Reports Q3 Loss, Tops Revenue Estimates
2021-11-03 19:53ConforMIS (CFMS) delivered earnings and revenue surprises of 0.00% and 1.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Conformis Reports Third Quarter 2021 Financial Results
2021-11-03 16:05BILLERICA, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the third quarter ended September 30, 2021.
ConforMIS (CFMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2021-10-27 16:11ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conformis (CFMS) to Post Q3 Earnings: What's in the Offing?
2021-10-26 11:51Conformis' (CFMS) third-quarter results are likely to reflect strength in core products.
Conformis, Inc. to Release Third Quarter 2021 Financial Results on November 3, 2021
2021-10-04 17:00BILLERICA, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the third quarter ended September 30, 2021 after the market closes on November 3, 2021 at approximately 4:00 p.m. Eastern Time.
Conformis (CFMS) Sees Hammer Chart Pattern: Time to Buy?
2021-10-04 08:45Conformis (CFMS) has been struggling lately, but the selling pressure may be coming to an end soon.
Conformis Posts Clinical Study Data For Its Knee Implants
2021-09-30 09:24Conformis Inc (NASDAQ: CFMS) announced results of a published retrospective study of procedures using Conformis' patient-specific iTotal CR (cruciate-retaining) knee replacement implant. Data showed that implant survivorship was 98.5% with 8 revisions (representing 1.5% of the 540 implants reviewed) at a mean follow-up of 2.8 years.
Conformis, Inc. Announces Strong Clinical Study Results for Its Personalized Knee Implants
2021-09-29 17:00A retrospective review of 540 procedures performed demonstrated 98.5% Implant Survivorship and 89.0% Patient Satisfaction for the Conformis patient-specific iTotal® CR (cruciate-retaining) knee replacement implants at mid-term follow-up A retrospective review of 540 procedures performed demonstrated 98.5% Implant Survivorship and 89.0% Patient Satisfaction for the Conformis patient-specific iTotal® CR (cruciate-retaining) knee replacement implants at mid-term follow-up